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High-performance liquid chromatography (HPLC) is a recently introduced high-capacity automated method for detecting unknown
mutations (denaturing HPLC) or for sizing DNA fragments under nondenaturing conditions. We have adapted the HPLC method for
detection of loss of heterozygosity (LOH) and used glial tumours as a model to evaluate its sensitivity and specificity in comparison to
conventional denaturing polyacrylamide gel electrophoresis. A total of 20 oligodendrogliomas (grades II and III), and five astrocytic
tumours (grades III and IV) were analysed using 14 polymorphic microsatellite markers mapping to regions on chromosomes 1p, 19q,
and 10q using both DNA-HPLC and denaturing gel electrophoresis. This study demonstrated complete concordance between both
methods. However, unlike gel electrophoresis, HPLC is automated, does not require post-PCR processing, and does not require
hazardous radioactive or expensive fluorescent labelling. Our data suggest that HPLC is a reliable and sensitive method for detection
of allelic losses in tumour samples and it is a favourable alternative for high-sensitivity LOH detection in both research and diagnostic
environments.
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Molecular genetic analysis of tumours frequently demonstrates
that regions of chromosomes that were heterozygous in constitu-
tional cells from patients become homozygous in the tumour (Pal
et al, 1990; Wadey et al, 1990; Grundy et al, 1998). This loss of
heterozygosity (LOH) has frequently been shown to result in the
loss of the chromosome region that contains the normal allele of a
gene critical for tumourigenesis. This mechanism results in the
‘exposure’ of recessive mutations in the homologous gene on the
remaining chromosome (Cavenee et al, 1983; Solomon et al, 1987;
Xu et al, 1992; Kelsell et al, 1993). These observations have been so
consistent that LOH analysis has now become a primary tool to
identify regions of chromosomes thought to harbour genes
responsible for the development and progression of a wide variety
of tumours. Recently, LOH has also been used as a diagnostic tool
to predict whether anaplastic oligodendrogliomas (AO) will be
sensitive or resistant to chemotherapy (Cairncross et al, 1998;
Smith et al, 2000). In these studies, AO showing LOH for the short
arm of chromosome 1 (1p) invariably demonstrate a positive
response to chemotherapy, whereas patients who have retained
heterozygosity in their tumours were resistant to chemotherapy.
This particular LOH assay provides a very important test for the
clinical management of patients with AO. Clearly, however, it is
essential to establish the LOH status of these tumours quickly and
accurately in order to be able to customise therapy and begin it in
a reasonable time following biopsy.
Currently, the main method used to establish the LOH status of
tumours involves using microsatellite repeat marker analysis from
DNA isolated either from fresh tissue or paraffin-embedded
sections. These techniques typically require radioactive polymer-
ase chain reaction (PCR) amplification, acrylamide gel analysis
and autoradiography of the region containing the microsatellite
repeat. Depending on the particular marker used, the results are
sometimes difficult to interpret because of the ‘stutter’ bands that
can accompany the alleles (especially when alleles are similar in
size), which results from slippage of the template during PCR
amplification. This whole procedure can also be time consuming.
Despite these limitations, this technology is still the most
frequently used to define regions of LOH.
Recently, it has become possible to eliminate the use of gels,
radioactivity, and autoradiography by adapting DNA-high-perfor-
mance liquid chromatography (DNA-HPLC) approaches to the
analysis of DNA fragments. The Transgenomics WAVE system, for
example, provides an automated way to perform heteroduplex
analysis that can detect mismatches between paired samples. This
procedure has found more extensive use as a quick and reliable
way of identifying mutations in PCR products amplified from
specific genes (O’Donovan et al, 1998; Arnold et al, 1999; Choy
et al, 1999; Gross et al, 1999). However, DNA samples from cells
that are heterozygous for microsatellite markers contain different
sized alleles, and so the question, therefore, is whether allelic loss
can be identified using HPLC in order to streamline the
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yidentification of LOH in tumour samples. To investigate this, we
have analysed polymorphic microsatellite markers from the short
arm of chromosome 1 (1p) and the long arm of chromosome 19
(19q) in order to determine whether it is possible to adapt the
HPLC analysis to the problem of predicting chemosensitivity in
AO. Here we report that, with the appropriate selection of
microsatellites and the correct conditions of the temperature
gradient, LOH can clearly be established efficiently and far more
quickly than using conventional approaches.
MATERIALS AND METHODS
Tumour samples and DNA isolation
Brain tumour tissues and peripheral blood samples were obtained
at the time of surgery from patients attending the Cleveland Clinic
Foundation Department of Neurosurgery. Representative tumour
samples were snap frozen and stored at  701C. Blood lymphocytes
were purified using Ficoll gradients from 3–5ml of heparin-
treated blood and stored at  701C in 10% DMSO. DNA was
isolated from frozen or fresh lymphocytes or tumour tissues using
DNA-Easy reagents (Invitrogen) according to the manufacturer’s
instructions.
Microsatellite markers
A total of 14 genetically mapped dinucleotide and tetranucleotide
microsatellite markers were used for LOH analysis. The genetic
location, primer sequences, and the size of the product of each
marker were obtained from the Genome Database (http://
gdbwww.gdb.org/). Primers were synthesised commercially (Re-
search Genetics, Inc., AL, USA; Genosys Biotechnologies Inc., TX,
USA).
Microsatellite HPLC analysis
Polymerase chain reaction was performed in a volume of 25ml
containing 1 Taq buffer, 100ng of genomic DNA, 0.2mM
each primer, 1.7mM MgCl2, 200mM each dNTP. 1.0 U of Taq
(Gibco, BRL) and 0.2 U of Pfu (Promega) polymerases.
Amplification was performed in a PTC-100 thermocycler (MJ
Research Inc., MA, USA). Cycling was performed with an
initial denaturation step of 3min at 941C followed by 30 cycles
of 941C for 45s, 561C for 30s, and 721C for 50s and then an
extension step at 721C for 3min. High-performance liquid
chromatography analysis was carried out on the automated
WAVEt DNA Fragment Analysis System (Transgenomics, Inc.,
CA, USA). Polymerase chain reaction products were separated
using a flow rate of 0.9mlmin
 1 over a period of 5–10min
through a linear acetonitrile gradient consisted of a mixture of
0.1 M triethylamine acetate (pH 7.0) without (buffer A) or with
(buffer B) 25% acetonitrile. The values for the buffer gradient were
calculated by the WaveMaker software according to the size of the
amplicon. The temperature of separation column was fixed at
501C, which is the temperature recommended for size separation
by the manufacturer.
Microsatellite electrophoresis analysis
Polymerase chain reaction amplification of the markers was
performed in 25ml containing 50ng of genomic DNA, 0.2mM of
each primer (one of them end-labelled with g-
32P), 1.7mM MgCl2,
200mM each dNTP, 1 amplification buffer, and 0.5U of TaI
polymerase (Gibco, BRL). Cycling was performed as described
above. The products of the PCR reaction were mixed with an equal
volume of formamide loading buffer (95% formamide, 20mM
EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol), denatured
at 951C for 5min, and cooled on ice. A volume of 3ml of each
sample was loaded on a 6% polyacrylamide gel containing 8 M urea
and electrophoresed for 2.5h at 65W. Gels were dried and exposed
to Kodak XAR film for 4–24h.
RESULTS AND DISCUSSION
For routine clinical diagnostic use, it is necessary for test
procedures to be quick and accurate and relatively inexpensive.
We set out to establish, therefore, using brain tumours as an
example whether ion-pair(IP)-reverse phase (RP) HPLC could be
used for detection of LOH in a variety of brain tumours. Loss of
heterozygosity analysis was performed using paired DNA samples
from tumour and blood from 25 patients with glial tumours.
Polymerase chain reaction products were generated from micro-
satellite markers from chromosomes 1p, 19q, and 10q (Table 1)
and then subjected to IP-RP HPLC under nondenaturing condi-
tions (501C). The elution profiles for the PCR products from each
of the microsatellites were compared to the gel patterns obtained
for the same markers using standard denaturing polyacrylamide
gel electrophoresis of
32P-labelled PCR fragments. Figure 1 shows
examples of the elution profiles (chromatograms) and correspond-
ing gel patterns of PCR fragments from a series of tumours with or
without LOH for the D1S551 marker. Two allelic microsatellite
fragments (heterozygous) were detected in the constitutional DNA
of patient ccf 97 after separation of
32P-labelled PCR products on
denaturing acrylamide gel. High-performance liquid chromato-
graphy analysis of the same DNA sample under nondenaturing
conditions shows three peaks on the elution profile. Peaks 2 and 3
correspond to the homoduplexes derived from the two different
sized alleles. Peak 1 represents the heteroduplex formed between
the two different sized PCR products during the last cycle of the
PCR reaction. Because of the mismatches in the heteroduplex,
Table 1 Loss of heterozygosity (LOH) frequencies of the 1p, 19q, and 10q markers in gliomas
Marker Chromosome Repeat type, bp ODG II–III GBM AA MOA
D1S552 1p36 4 7
a/14
b 1/3 0/1 1/3
D1S1612 1p36 4 6/11 1/3 0/2 0/2
D1S468 1p36 2 4/8 1/2 ND 0/2
D1S551 1p31 4 8/9 1/4 0/1 1/4
D1S430 1p31 2 4/9 0/2 0/1 1/2
D19S254 19q13.4 4 6/9 1/2 0/3 0/4
D19S572 19q13.4 2 2/3 2/3 ND ND
D10S587 10q26 2 0/5 3/4 ND ND
D10S209 10q25 2 2/6 2/3 ND ND
Tumours analysed 18 4 3 5
ODG¼oligodendroglioma grades II and III; GBM¼glioblastoma multiforme: AA¼anaplastic astrocytoma; MOA¼mixed
oligoastrocytoma.
aNumber of samples with LOH.
bNumber of informative samples.
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ythese molecules have a reduced retention time on the column and
so are eluted ahead of the homoduplexes. In this example, ccf 97,
the profiles are identical in both tumour and normal DNA
indicating that there has been no LOH. The example shown for ccf
117 reveals that using acrylamide gels the patient is homozygous
for the D1S551 marker (Figure 1) and a single peak is seen on the
HPLC chromatogram. This patient is referred to as ‘not
informative’ since it cannot be established whether an allele has
been lost or not. Tumours where LOH can be detected were
derived from patients ccf 12, ccf 99, and ccf 113. In all of these
cases, loss of one allele is indicated by a significant reduction in the
size of one of the homoduplexes, which is accompanied by a
reduction or elimination of the heteroduplex signal (Figure 1). It is
likely that the presence of a residual band in the heteroduplex, for
example, in ccf 12, is due to low-level contamination by normal
cells in the original tumour sample. As with all LOH approaches,
the percentage of contaminating normal cells will affect the
appearance of the elution profile, although in our studies this has
not been a significant problem. It appears that reduction/
elimination of the heteroduplex signal is a very accurate and
sensitive indicator of LOH, especially in cases (e.g. ccf 12) where,
because of the small difference in allele sizes, both homoduplex
peaks are poorly separated (Figure 1). It is clear from these studies
that there is excellent concordance between HPLC and denaturing
gel analysis. In the initial studies, we used the microsatellite
marker D1S551 that was known from our previous analysis to
generate discrete PCR products for each of the alleles. This is not
always the case with microsatellite markers since, because of the
highly repetitive nature of the repeat they contain, template
slippage often occurs, which results in ‘stutter’ bands on either side
of the main PCR product. To test the influence this would have on
the HPLC elution profile, we analysed a number of different
microsatellite markers (Table 1) that mapped to chromosomes 1p,
19q, and 10q. These markers are spread across regions that
frequently show LOH in glial tumours. It can be seen from the
representative chromatograms shown in Figure 2 that a variety of
marker-specific elution profiles are generated. Some markers, for
example, D1S552 (Figure 2), have heterozygous elution profiles
that showed the typical three peaks similar to D1S551, and so LOH
is easily seen. Other profiles, such as the ones for D1S468 and
D1S430, show the stutter peaks but with considerably reduced
intensity and so these can effectively be ignored. In fact, the shape
of the chromatogram depends on three factors: (1) the size
difference between two allelic variants (heteroduplex formation is
suppressed when the size of the two alleles are very different), (2)
primary/secondary structure of the PCR fragment, and (3) the
abundance of the stutter PCR products. Despite the complex
patterns of elution profiles, loss of one allele in heterozygous
samples is always easily detectable, since the retained allele
produces only a single peak. Despite the generally consistent
observation that loss of the heteroduplex peak indicates LOH, for
some microsaellite markers this was not the case. An example is
shown in Figure 2 for the D19S254 marker. In this case, a
heteroduplex is apparently not formed, or coelutes with one of the
homoduplex peaks. In this case, however, LOH can still easily be
detected based on the loss of one of the peaks in both ccf 93 and ccf
138. This rare elution profile underscores the need to select
markers for LOH studies carefully and to determine their elution
profiles empirically.
Importantly, we have been able to show that the elution profile
for any given marker is highly reproducible in parallel HPLC runs.
Furthermore, tumour samples that have retained both chromo-
somes demonstrate elution profiles almost identical to the
corresponding blood DNAs. The other important point is that
any change in the elution profile in the tumour samples invariably
indicated loss of one allele. Clearly, the choice of the marker to be
used is important since some microsatllites, regardless of which
technique is used, produce band profiles which cannot be
interpreted. It is usually necessary, therefore, to identity several
microsatellite markers from the region of interest if possible, and
then select the ones that give the clearest results for routine testing.
In addition to the nine markers listed in Table 1, we also analysed
12 more markers and found that some of them (D1S224, D1S216,
D10S185, D19S216, and D19601) produce easily readable elution
profiles (data not shown) and can also be used for LOH analysis.
Our original reason for adapting the WAVE technology to the
detection of LOH using microsatellite markers was to investigate
its applicability to the analysis of brain tumours to determine their
chemosensitivity. We therefore selected nine markers from
chromosomes 1p, 19q, and 10q and analysed LOH status for 30
pairs of blood and glial tumour DNA using the WAVE system. In
all, 82% (125 of 152) of these analyses demonstrated constitutional
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Figure 1 Comparison of LOH analysis using DNA-HPLC and denaturing
polyacrylamide gel electrophoresis. Examples from five tumours using
marker D1S551 are shown. DNA from peripheral blood (B) or tumour (T)
were analysed by both methods. Electrophoresis results are shown on the
right. The relevant portions of the corresponding HPLC elution profiles are
shown on the left in each example. Peaks 2 and 3 represent the two allelic
homoduplexes of D1S551 in normal DNA from individuals heterozygous
for the marker. Peak 1 represents a heteroduplex with shorter retention
time. Tumour ccf 117 is constitutionally homozygous and shows only one
peak. Tumour ccf 12 is heterozygous, but the two alleles differ in size by
only four base pairs and so the two allelic peaks in this case do not resolve
as well as in the other examples shown. In the three tumours showing
LOH, the presence of a single peak in the tumour indicating the retained
allele together with the loss of the heteroduplex peak can be clearly seen.
The elution time (min) is represented on the x-axis, and the ultraviolet
absorbance at 260nm is represented on the y-axis (in mV).
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summarises the informative cases, divided into morphological
subtype, showing loss of the respective 1p, 19q, and 10q regions. In
our analysis we focused mainly on oligodendroglial tumours,
although other types of glial tumours were also included.
Oligodendrogliomas grades II and III showed loss of 1p in 10 of
18 (55%) tumours, and loss of 19q in 7 of 12 (58%) informative
cases. All tumours with 19q allelic loss also demonstrated LOH on
1p. These data are in agreement with recent reports that
demonstrated the loss of 1p and 19q in 40–80% of oligoden-
droglial tumours (Ransom et al, 1992; Reifenberger et al, 1994;
Kraus et al, 1995; Zhu et al, 1998). Since this is a prospective study,
details about response to therapy and prognosis are not available
at this time. Unlike astrocytic tumours (Fults and Pedone, 1993;
Karlbom et al, 1993; Rasheed et al, 1995; Kimmelman et al, 1996;
Ichimura et al, 1998), which demonstrate frequent loss of 10q (up
to 80% in glioblastoma multiforme (GBM)), oligodendrogliomas
have been less completely characterised (Maier et al, 1997;
Rasheed et al, 1999). Although we have only analysed a few
tumours, since the focus of this study was to compare WAVE
analysis with gel analysis, we nonetheless found loss of 10q in
two of five oligodendrogliomas and two of two 2 GBMs. 42%
of the microsatellite loci analysed in this study were also analysed
using standard polyacrylamide gel electrophoresis and, in all
cases, the results were completely concordant with those from the
HPLC.
The analysis of these brain tumours revealed an important detail
that reinforces the need to carefully select the microsatellites to be
used in WAVE-LOH. From the results in Table 1, several of the
markers, for example, D19S572 and D10S587, showed relatively
few heterozygotes in our small series. All of these markers
represent dinucleotide repeats that supposedly have a hetero-
zygosity frequency of over 70% in the general population.
Although it is possible that the decreased frequency of observed
heterozygotes is a consequence of sampling bias in this small
population, it is also possible that for some markers where the size
differences between alleles are small, HPLC may not be able to
resolve the individual alleles. The frequency of heterozygotes for
the tetranucleotide repeats markers, however, were generally close
to those expected. Clearly, if the analysis permits, it would be
preferable to use this type of marker in this application of LOH
analysis.
In summary, this study demonstrates that HPLC is a reliable
and sensitive alternative for the detection of allelic losses in
tumour samples. It is usually necessary to screen several
microsatellite markers from the same interval if possible
since some, despite which chromosome region is selected, are
difficult to interpret regardless of the method used. Importantly,
unlike denaturing gel electrophoresis, HPLC analysis is automated,
does not require post-PCR processing, and does not
require radioactive or expensive fluorescence labelling. This
technique is also less prone to artefacts produced by technical
problems with creating and running gels, such as edge
effects or incomplete polymerisation, which, might further
complicate the analysis of the results. High-performance liquid
chromatography, therefore, is a very favourable alternative for
rapid, high-throughput LOH detection in both research and
diagnostic environments.
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